ArticleDiagnostics (Basel, Switzerland)2021
Pentraxin-3 Is a Strong Biomarker of Sepsis Severity Identification and Predictor of 90-Day Mortality in Intensive Care Units via Sepsis 3.0 Definitions.
Article in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Recent advances in the biosensing platforms for sepsis diagnosis.RSC advances · 2026Review
- Longitudinal biomarker trajectories and their prognostic utility for 21-day mortality in burn patients with sepsis: a retrospective cohort study.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Clusterin and pentraxin 3 are markers of severity during febrile neutropenia in adults with haematological malignancies receiving intensive chemotherapy.British journal of haematology · 2025Article
- Time- and temperature-dependent Pentraxin 3 stability in serum and bronchoalveolar lavage fluid samples.Medical mycology · 2025Article
- Article
- Pentraxin-3 as a novel prognostic biomarker in non-neutropenic invasive pulmonary aspergillosis patients.Microbiology spectrum · 2025Article
- Resistin as a potential diagnostic biomarker for sepsis: insights from DIA and ELISA analyses.Clinical proteomics · 2024Article
- Review
- Progress in the study of pentraxin-3(PTX-3) as a biomarker for sepsis.Frontiers in medicine · 2024Review
- Long Pentraxin 3 as a New Biomarker for Diagnosis of Hip and Knee Periprosthetic Joint Infections.Journal of clinical medicine · 2023Article
- Biomarkers of Sepsis.Diagnostics (Basel, Switzerland) · 2023Article
- The Predictive Value of Heparin-Binding Protein and D-Dimer in Patients with Sepsis.International journal of general medicine · 2023Article
- Article
- Long pentraxin 3 (PTX3) levels predict death, intubation and thrombotic events among hospitalized patients with COVID-19.Frontiers in immunology · 2022Article
- A cytokine/PTX3 prognostic index as a predictor of mortality in sepsis.Frontiers in immunology · 2022Article
- Diagnostic and therapeutic value of biomarkers in urosepsis.Therapeutic advances in urologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSepsis is the leading cause of mortality in intensive care units (ICUs). However, early diagnosis and prognosis of sepsis and septic shock are still a great challenge. Pentraxin-3 (PTX3) was shown to be associated with the severity and outcome of sepsis and septic shock. This study was carried out to investigate the diagnostic and prognostic value of PTX3 in patients with sepsis and septic shock based on Sepsis 3.0 definitions.
methodsIn this single-center prospective observational study, all patients' serum was collected for biomarker measurements within 24 h after admission. Logistic and Cox regression analyses were used to identify the potential biomarkers of diagnosis, severity stratification, and prediction.
resultsSerum levels of PTX3 were significantly increased on the first day of ICU admission, while septic shock patients had highest PTX3 levels than other groups. A combination between PTX3 and procalcitonin (PCT) could better discriminate sepsis and septic shock, and PTX3 was an independent predictor of mortality in sepsis and septic shock patients.
conclusionPTX3 may be a robust biomarker to classify the disease severity and predict the 90-day mortality of sepsis and septic shock based on the latest Sepsis 3.0 definitions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.